NLS Global report

The offer values PolyPeptide's equity at approximately CHF 1.46 billion.

Merck and Bio-Techne Corporation have entered into a definitive agreement pursuant to which Merck will, subject to customary closing conditions, acquire Bio-Techne for USD 73 per share in cash, representing a total enterprise value of approximately USD 11.3 billion, a 36% premium to Bio-Techne’s one-month volume weighted average trading price.

After more than four years of full-scale war waged by Russia in Ukraine, Ukrainians’ physical and mental health – and the entire healthcare system – are under extreme pressure. Today, relief efforts focus on knowledge transfer, new ways of managing and operating healthcare, and long-term partnerships, while also drawing lessons from Ukraine’s own resilience, crisis responses, and rehabilitation solutions.

NLS asked Azza Chammem, Associate Director at Scope Ratings, a European credit rating agency, how the current conflict in the Middle East has affected the life science industry and what the future effects might be.

SOPHiA Genetics has signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) relating to the formation of a joint venture between the two institutions. 

Johnson & Johnson has announced it has entered into a definitive agreement to acquire Firefly Bio, biotech company advancing its Firelink degrader antibody conjugate (DAC) platform, for USD 1 billion in cash.